• By ICR Secretariat
  • Posted Thursday, March 11, 2021

Biotech's deal refusals led to pricey buyout by Merck


  • Pandion Therapeutics, a small Massachusetts biotech, successfully resisted multiple overtures by pharmaceutical giant Merck & Co. to license or acquire its research, pushing the larger company to pay a sizable premium in the $1.85 billion buyout deal announced last month.